Newsroom

Perspective: Addressing oligonucleotide development challenges from a CRDMO's perspective

An invitation to the WuXi TIDES forum in London

WuXi STA Opens a New Sterile Lipid Nanoparticle Formulation Facility to Enhance Global CRDMO Services for Customers

WuXi AppTec Plans to Build a New Site in Singapore, Better Serving Global Partners and Advancing Healthcare Innovation

WuXi STA Opens New Large-scale Oligonucleotide and Peptide Manufacturing Facility

Expansion Plan Annouced at DCAT Including Oligonucleotide